# Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy

> **NCT01677377** · PHASE2 · COMPLETED · sponsor: **Indivior Inc.** · enrollment: 45 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone
- **DRUG:** RBP-7000

## Key facts

- **NCT ID:** NCT01677377
- **Lead sponsor:** Indivior Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2018-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01677377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01677377, "Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01677377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*